Division of Plastic & Reconstructive Surgery, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Ann Surg. 2022 Oct 1;276(4):635-653. doi: 10.1097/SLA.0000000000005591. Epub 2022 Jul 15.
While vascularized lymph node transplant (VLNT) has gained popularity, there are a lack of prospective long-term studies and standardized outcomes. The purpose of this study was to evaluate the safety and efficacy of VLNT using all available outcome measures.
This was a prospective study on all consecutive patients who underwent VLNT. Outcomes were assessed with 2 patient-reported outcome metrics, limb volume, bioimpedance, need for compression, and incidence of cellulitis.
There were 89 patients with the following donor sites: omentum (73%), axilla (13%), supraclavicular (7%), groin (3.5%). The mean follow-up was 23.7±12 months. There was a significant improvement at 2 years postoperatively across all outcome measures: 28.4% improvement in the Lymphedema Life Impact Scale, 20% average reduction in limb volume, 27.5% improvement in bioimpedance score, 93% reduction in cellulitis, and 34% of patients no longer required compression. Complications were transient and low without any donor site lymphedema.
VLNT is a safe and effective treatment for lymphedema with significant benefits fully manifesting at 2 years postoperatively. Omentum does not have any donor site lymphedema risk making it an attractive first choice.
血管化淋巴结移植(VLNT)已得到广泛应用,但缺乏前瞻性长期研究和标准化的结局评估。本研究旨在通过使用所有可用的结局评估指标,评估 VLNT 的安全性和有效性。
这是一项对所有连续接受 VLNT 的患者进行的前瞻性研究。使用 2 种患者报告结局指标(肢体体积、生物阻抗、对压缩的需求和蜂窝织炎发生率)评估结局。
89 例患者的供体部位如下:大网膜(73%)、腋窝(13%)、锁骨上(7%)、腹股沟(3.5%)。平均随访时间为 23.7±12 个月。所有结局指标在术后 2 年均有显著改善:淋巴水肿生活影响量表改善 28.4%,肢体体积平均减少 20%,生物阻抗评分改善 27.5%,蜂窝织炎减少 93%,不再需要压缩的患者比例为 34%。并发症短暂且轻微,无供体部位淋巴水肿。
VLNT 是一种安全有效的淋巴水肿治疗方法,术后 2 年时疗效显著。大网膜不存在供体部位淋巴水肿风险,是理想的首选供体部位。